Lixisenatide
Indication
Type 2 diabetes mellitus
Suitable for initiation in primary care in line with restrictions (see background paragraph)
Green
Brand:
Lyxumia®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Lixisenatide is not a preferred product in the LSCMMG antihyperglycaemics guideline.
Lixisenatide recommended as an option in line with NICE guideline NG28.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: